首页> 外文期刊>British Journal of Clinical Pharmacology >Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration.
【24h】

Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration.

机译:静脉给药后血液透析和腹膜透析患者中​​达贝泊汀α的群体药代动力学。

获取原文
获取原文并翻译 | 示例
           

摘要

Aims To characterize the pharmacokinetics of darbepoetin alfa and covariate relationships in haemodialysis (HD) and peritoneal dialysis (PD) patients. Methods Data were collected from 131 (63 HD and 68 PD) patients who received darbepoetin alfa intravenously. A total of 917 serum concentrations were available. The data were analysed by nonlinear mixed effect modelling using NONMEM with a model including endogenous erythropoietin production. In addition, the final model was evaluated using bootstrap resampling. Results The selected basic model was a two-compartment model with a combination of additive and the constant coefficient of variation error models. The significant covariates were weight (WT) for clearance (CL) and the volume of central compartment (V(1)), and the dialysis technique (DIA) for V(1). The typical values of CL and V(1) were 0.0807 l h(-1) and 2.51 l, respectively. V(1) in PD patients was 17% higher than in HD patients. With the introduction of WT in CL and WT and DIA in V(1), interindividual variability decreased from 27.1% to 20.6% in CL and from 29.1% to 21.8% in V(1). The mean parameter estimates from the bootstrap datasets were similar to those from the original dataset. Evaluation by bootstrapping showed that the final model was stable. Conclusions The results of the present analysis suggest no dosage regimen change is warranted for darbepoetin alfa in HD and PD patients over the range of distribution of covariates included in this study.
机译:目的表征血液透析(HD)和腹膜透析(PD)患者中达贝泊汀α的药代动力学和协变量关系。方法收集131例静脉注射达比泊汀阿尔法的患者(63例HD和68例PD)的数据。共有917个血清浓度可用。通过使用NONMEM的非线性混合效应模型以及包含内源促红细胞生成素的模型对数据进行了分析。此外,使用引导重采样对最终模型进行了评估。结果选择的基本模型是一个两室模型,具有相加模型和常数变异系数模型。显着的协变量是重量(WT)的清除率(CL)和中央隔室的体积(V(1)),以及透析技术(DIA)的V(1)。 CL和V(1)的典型值分别为0.0807 l h(-1)和2.51 l。 PD患者的V(1)比HD患者高17%。随着CL中引入WT以及V(1)中引入WT和DIA,CL中个人间的变异性从27.1%降低到20.6%,而V(1)中个体间的变异性从29.1%降低到21.8%。引导数据集的平均参数估计与原始数据集的平均参数估计相似。通过自举进行评估表明最终模型是稳定的。结论本分析的结果表明,在本研究包括的协变量分布范围内,HD和PD患者的darbepoetin alfa无需改变剂量方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号